Effects of non-glycated and glycated glucagon-like peptide-1(7-36) amide on glucose metabolism in isolated mouse abdominal muscle

Peptides

Volumn 18, Issue 9, 1997, Pages 1327-1333

  O'Harte, Finbarr P M ^a   Gray, Alison M ^a   Abdel Wahab, Yasser H A ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Abdominal muscle; GLP 1(7 36)amide; Glucose metabolism; Glycation

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE;

ABDOMINAL WALL MUSCULATURE; ANIMAL EXPERIMENT; ARTICLE; GLUCOSE HOMEOSTASIS; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLYCOGENOLYSIS; HUMAN; MALE; MOUSE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION;

ABDOMINAL MUSCLES; ANIMALS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLUCOSE; GLYCOSYLATION; INSULIN; MALE; MICE; OXIDATION-REDUCTION; PEPTIDE FRAGMENTS; PEPTIDES;

EID: 0030691128     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(97)00201-5     Document Type: Article

References (48)

1. Abdel-Wahab Y. H. A., O'Harte F. P. M., Ratcliff H., McClenaghan N. H., Barnett C. R., Flatt P. R. Glycation of insulin in the islets of Langerhans of normal and diabetic animals. Diabetes. 45:1996;1489-1496.
2. Abdel-Wahab Y. H. A., O'Harte F. P. M., Barnett C. R., Flatt P. R. Characterization of insulin glycation in insulin-secreting cells maintained in tissue culture. J. Endocrinol. 152:1997;59-67.
3. Adelhorst K., Hedegaard B. B., Knudsen L. B., Kirk O. Structure-activity studies of glucagon-like peptide-1. J. Biol. Chem. 269:1994;6275-6278.
4. Bell G. I., Sanchez-Pescador R., Laybourn P. J., Najarian R. C. Exon duplication and divergence of the human preproglucagon gene. Nature. 304:1983;368-371.
5. D'Alessio D. A., Kahn S. E., Leusner C. R., Einsinck J. W. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-dependent glucose disposal. J. Clin. Invest. 93:1994;2263-2266.
6. Deacon C. F., Johnsen A. H., Holst J. J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous peptide in vivo. J. Clin. Endocrinol. Metab. 80:1995;952-957.
7. Delgado E., Luque M. A., Alcántara A. I., Trapote M. A., Clemente F., Galera C, Valerde I., Villanueva-Penacarrillo M. L. Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides. 16:1995;225-229.
8. Drucker D. J., Philippe J., Mojsov S., Chick W. L., Habener J. F. Glucagon-like peptide-1 stimulates insulin gene expression and increases cyclic AMP levels in a rat cell line. Proc. Natl. Acad. Sci. USA. 84:1987;3434-3438.
9. Fehmann H-C., Göke R., Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocrine Rev. 16:1995;390-410.
10. Flatt, P. R.; Abdel-Wahab, Y. H. A.; Wilson, A. M.; Barnett, C. R.; O'Harte, F. P. M.; Swanston-Flatt, S. K. Site-specific defects and glucose toxicity in pancreatic B-cell dysfunction of non-insulin dependent diabetes mellitus. In: Flatt, P. R.; Lenzen, S.; Eds. Frontiers of insulin secretion and pancreatic B-cell research. London: Smith-Gordon & Co. Ltd; 1994:481-489.
11. Fürnsinn C., Ebner K., Waldhäusl W. Failure of GLP-1(7-36)amide to affect glycogenesis in rat skeletal muscle. Diabetologia. 38:1995;864-867.
12. Galera C., Clemente F., Alcántara A., Trapote M. A., Perea A., Lopez-Delgado M. I., Villanueva-Penacarrillo M. L., Valverde I. Inositolphosphoglycans and diacylglycerol are possible mediators of the glycogenic effect of GLP-1(7-36)amide in BC3H-1 myocytes. Cell Biochem. Funct. 14:1996;43-48.
13. Gallwitz B., Witt M., Schmidt W. E. Binding of GLP-1(7-36)amide analogues and GLP-1/GIP hybrid peptides to RINm5F insulinoma cells. Digestion. 54:1993;345.
14. Gallwitz B., Witt M., Morys-Wortmann C., Foelsch U. R., Schmidt W. E. GLP-1-GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1. Regul. Peptides. 63:1996;17-22.
15. Gefel D., Hendrick G. K., Mojsov S., Habener J., Weir G. C. Glucagon-like peptide-1 analogs effects on insulin secretion and 3′;5′-monophosphate formation . Endocrinology. 126:1990;2164-2168.
16. Göke R., Conlon J. M. Receptors for glucagon-like peptide-1 (7-36)amide on rat insulinoma-derived cells. J. Endocrinol. 116:1988;357-362.
17. Grandt D., Sieburg B., Schimiczek M., Becker U., Holtmann G., Layer P., Reeve J. R. Jr, Eysselein V. E., Goebell H., Mueller M. Is GLP-1(9-36)amide an endogenous antagonist at GLP-1 receptors? Digestion. 55:1994;302.
18. Gromada J., Dissing S., Bokvist K., Renstrom E., Frokjaer-Jensen J., Wulff B. S., Rorsman P. Glucagon-like peptide 1 increases cytoplasmic calcium in insulin secreting beta-TC3-cells by enhancement of intracellular calcium mobilization. Diabetes. 44:1995;767-774.
19. Gutniak M., Orskov C., Holst J. J., Ahrén B., Efendic S. Antidiabetogenic effect of glucagon-like peptide 1 (7-36)amide in normal subjects and patients with diabetes mellitus. New Engl. J. Med. 326:1992;1316-1322.
20. Holz G. G., Kühtreiber W. M., Habener J. F. Pancreatic beta cells are rendered glucose competent by insulinotropic hormone glucagon-like peptide-1(7-37). Nature. 361:1995;362-365.
21. Hunter S. J., Wiggam M. I., Boyd A. C., O'Harte F. P. M., Ennis C. N., Gamble R., Sheridan B., Barnett C. R., McNulty H., Bell P. M., Flatt P. R. Glycation of human insulin reduces its biological potency as assessed by euglycaemic clamps in normal man. Diabetic Med. 13:1996;S17-S18.
22. Kanse S. M., Kreymann B., Ghatei M. A., Bloom S. R. Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in rat brain and lung. FEBS Lett. 241:1988;209-212.
23. Kieffer T. J., McIntosh C. H. S., Pedersen R. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide-1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 136:1995;3585-3596.
24. Komatsu R., Matsuyama T., Namba M., Watanabe N., Itoh H., Kono N., Tarui S. Glucagonostatic and insulinotropic action of glucagon-like peptide1-(7-36)amide. Diabetes. 38:1989;902-905.
25. Marchand-Brustel Y. M., Freychet P. Regulation of glycogen synthase activity in the isolated mouse soleus muscle. Effect of insulin, epinephrine, glucose and anti-insulin receptor antibodies. Biochim. Biophys. Acta. 677:1981;13-22.
26. Mentlein R., Gallwitz B., Schmidt W. E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214:1993;829-835.
27. Mojsov S., Heinrich G., Wilson I., Ravazzola O., Orci L., Habener J. F. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J. Biol. Chem. 261:1986;11880-11889.
28. Nauck M. A., Kleine N., Orskov C., Holst J. J., Willms B., Creutzfeldt W. Normalization of fasting hyperglycaemia by endogenous glucagon-like peptide 1 (7-36)amide in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 36:1993;741-744.
29. Oben J., Morgan L., Fletcher J., Marks V. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36)amide, on fatty acid synthesis in explants of rat adipose tissue. J. Endocrinol. 130:1991;267-272.
30. O'Harte F. P. M., Højrup P., Barnett C. R., Flatt P. R. Identification of the site of glycation of human insulin. Peptides. 17:1996;1323-1330.
31. O'Harte F. P. M., Abdel-Wahab Y. H. A., Flatt P. R. Glycation of glucagon-like peptide-1(7-36)amide impairs its insulinotropic action on glucose-responsive BRIN-BD11 cells. Diabetic Med. 13:1996;S4.
32. Ørskov C., Holst J. J., Knuthsen S., Baldissera F. G. A., Poulsen S. S., Vagn-Neilsen O. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene are secreted separately from the pig small intestine, but not pancreas. Endocrinology. 119:1986;1467-1475.
33. Ørskov C., Bersani M., Johnsen A. J., Højrup R., Holst J. J. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J. Biol. Chem. 264:1989;12826-12829.
34. Ørskov C., Poulsen S. S. Glucagon like peptide-1-(7-36)amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats. Diabetes. 40:1991;1292-1296.
35. Ørskov C. Glucagon like peptide-1, a new hormone of the enteroinsular axis. Diabetologia. 35:1992;701-711.
36. Roepstoff P. 252-Californium plasma desorbtion time-of-flight mass spectrometry of peptides and proteins. Methods Mol. Biol. 17:1993;229-235.
37. Schmidt W. E., Siegel E. G., Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia. 28:1985;704-707.
38. Suzuki S., Kawai K., Ohashi S., Mukai H., Yamashita K. Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. Endocrinology. 125:1989;3109-3114.
39. Thorens B., Waeber G. Glucagon-like peptide-1 and control of insulin secretion in the normal state and in NIDDM. Diabetes. 42:1993;1219-1225.
40. Thorens B. Glucagon-like peptide-1 and control of insulin secretion. Diabete et Metabolisme. 21:1995;311-318.
41. Toft-Nielsen M., Madsbad S., Holst J. J. The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes. 45:1996;552-556.
42. Turton M. D., O'Shea D., Gunn I., Beak S. A., Edwards C. M. B., Meeran K., Choi S. J., Taylor G. M., Heath M. M., Lambert P. D., Wilding J. P. H., Smith D. M., Ghatei M. A., Herbert J., Bloom S. R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 379:1996;69-72.
43. Valverde I., Morales M., Clemente F., Lopez-Delgado M. I., Delgado E., Perea A., Villanueva-Penacarrillo M. L. Glucagon-like peptide 1 a potent glycogenic hormone . FEBS Lett. 349:1994;313-316.
44. Villanueva-Peñacarrillo M. L., Alcántara A. I., Clemente F., Delgado E., Valverde I. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia. 37:1994;1163-1166.
45. Villanueva-Peñacarrillo M. L., Delgado E., Vincent D., Mérida E., Alcantara A. I., Valverde I. GLP-1(7-36)amide binding in skeletal muscle membranes from streptozocin diabetic rats. Endocr. J. 3:1995;685-687.
46. Watanabe Y., Kawai K., Ohashi S., Yokota C., Suzuki S., Yamashita K. Structure-activity relationships of glucagon-like peptide-1(7-36) insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells . J. Endocrinol. 140:1994;45-52.
47. Wettergren A., Schjoldajer B., Mortensen P. E., Myhre J., Christiansen J., Holst J. J. Truncated GLP-1 (proglucagon (78-107)amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 38:1993;665-673.
48. Williams, G.; Bloom, S. R. Somatostatin and pancreatic polypeptide. In: Alberti, K. G. M. M.; DeFronzo, R. A.; Keen, H.; Zimmett, P.; Eds. International textbook of diabetes mellitus. Chichester: John Wiley & Sons Ltd; 1992:341-355.